Karrar Kareem Gaen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Karrar Kareem Gaen has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Heider Qassam
Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Najaf, Iraq
2 shared publications - Najah Rayish Hadi
Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Najaf, Iraq
2 shared publications - Ahmed Mh Al-Mudhafar
Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Najaf, Iraq
1 shared publication - Ali M. Janabi
Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Kufa, Najaf, Iraq
1 shared publication - Ammar Azzam
Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Babylon, Babylon, Iraq
1 shared publication - Rihab Hameed Almudhafar
Department of Pathology and Forensic Medicine, Faculty of Medicine, University of Kufa, Kufa, Iraq
1 shared publication
Latest Publications
- 27 May 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
Ameliorative effects of bevacizumab against sepsis-induced acute kidney injury: investigation of inflammatory responses, pyroptosis-related signalling and angiogenesis in a murine model of polymicrobial sepsis
Sepsis is a clinical issue with a major impact on in-hospital patients, resulting in multiple organ damage and increased risk of death. Acute kidney injury (AKI) is the most common organ that is vulnerable to sepsis and may progress to renal failure if not treated. Bevacizumab is a biopharmaceutical agent that disrupts the angiogenesis signalling pathway by binding to vascular endothelial growth factor (VEGF) and preventing it from coupling with cognate receptors. The present study aimed to assess the renoprotective potential of bevacizumab against sepsis-induced renal injury. Four cohorts (6 mice per group) were randomly allocated and included a sham cohort, which was exposed to a midline incision only; the cecal ligation and puncture (CLP) cohort underwent CLP; the vehicle cohort was pretreated with normal saline 1 h prior to the CLP; and the bevacizumab cohort was treated with 0.1 mg/kg bevacizumab 1 h before the CLP. After 24 h, the mice were euthanised, and the blood and kidneys were collected. The results revealed that the levels of urea, creatinine, TNF-α, IL-6, caspase 11, ICAM-1, VEGF and angiopoietin-2 were greater in septic mice than in sham mice. These levels were decreased in septic mice pretreated with bevacizumab. Histological assessment of renal tissues revealed that the kidneys of septic mice were injured, influencing 90% of the renal tubules. Pretreatment with bevacizumab mitigated renal tissue damage. This study demonstrated that bevacizumab has promising renoprotective effects against sepsis-induced renal injury via modulation of inflammatory responses, angiogenesis and pyroptosis-associated signalling.
- 27 May 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
Ameliorative effects of bevacizumab against sepsis-induced acute kidney injury: investigation of inflammatory responses, pyroptosis-related signalling and angiogenesis in a murine model of polymicrobial sepsis
Sepsis is a clinical issue with a major impact on in-hospital patients, resulting in multiple organ damage and increased risk of death. Acute kidney injury (AKI) is the most common organ that is vulnerable to sepsis and may progress to renal failure if not treated. Bevacizumab is a biopharmaceutical agent that disrupts the angiogenesis signalling pathway by binding to vascular endothelial growth factor (VEGF) and preventing it from coupling with cognate receptors. The present study aimed to assess the renoprotective potential of bevacizumab against sepsis-induced renal injury. Four cohorts (6 mice per group) were randomly allocated and included a sham cohort, which was exposed to a midline incision only; the cecal ligation and puncture (CLP) cohort underwent CLP; the vehicle cohort was pretreated with normal saline 1 h prior to the CLP; and the bevacizumab cohort was treated with 0.1 mg/kg bevacizumab 1 h before the CLP. After 24 h, the mice were euthanised, and the blood and kidneys were collected. The results revealed that the levels of urea, creatinine, TNF-α, IL-6, caspase 11, ICAM-1, VEGF and angiopoietin-2 were greater in septic mice than in sham mice. These levels were decreased in septic mice pretreated with bevacizumab. Histological assessment of renal tissues revealed that the kidneys of septic mice were injured, influencing 90% of the renal tubules. Pretreatment with bevacizumab mitigated renal tissue damage. This study demonstrated that bevacizumab has promising renoprotective effects against sepsis-induced renal injury via modulation of inflammatory responses, angiogenesis and pyroptosis-associated signalling.
- Open Access
- 17 July 2025
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 26 (1) , 134
Dimethyl fumarate attenuates liver injury in a mouse model of cecal ligation and puncture by modulating inflammatory, angiogenic and pyroptotic pathways
Sepsis is a prevalent ailment that significantly affects hospitalized individuals around the globe. It is characterized by uncontrolled inflammatory responses resulting in organ injury and leading to high morbidity and mortality. The liver, a vital organ, is affected by sepsis, resulting in liver dysfunction. Dimethyl fumarate (DMF), which is approved for the treatment of multiple sclerosis, has anti-inflammatory and neuroprotective properties through the inhibition of multiple inflammatory mediators. Hence, the present study aimed to assess the hepatoprotective potential of DMF against sepsis. Four groups of mice (6 animals per group) were divided into a sham group, which was subjected to only anaesthesia and a midline abdominal incision; the cecal ligation and puncture (CLP) group was anaesthetized and underwent an abdominal incision followed by the ligation of the cecum under the ileocecal valve and perforation twice with a needle; the vehicle group was given a solvent of DMF 1 h before the CLP, and the CLP group received 50 mg/kg of DMF via intraperitoneal (ip) injection 1 h before CLP. Following the procedure (24 h post-CLP), the mice were given unrestricted access to food and drink throughout the day. Serum was used to measure the levels of angiopoietin 2, AST and ALT. Enzyme-linked immunosorbent assay (ELISA) was used to investigate the levels of TNF-α, IL-6, MIF, ICAM-1, F2-isoprostanes, VEGF, and caspase 11 in liver tissues. To evaluate the degree of liver damage, a biopsy of the liver was performed. The results revealed that mice exposed to CLP had high levels of AST and ALT in comparison with sham mice. Furthermore, levels of TNF-α, IL-6, MIF, ICAM-1, F2-isoprostanes, VEGF, and caspase 11 in liver tissues were also notably elevated as compared with sham mice. The levels of these parameters were significantly decreased in septic mice pre-treated with DMF. Mice with CLP showed a severe degree of liver damage as compared with sham mice. DMF pre-treatment mitigated liver injury. This study suggests that DMF has hepatoprotective effects on septic mice via the modulation of inflammation, adhesion molecules, angiopoietin 2 and pyroptosis.
- 17 July 2025
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 26 (1) , 134
Open AccessDimethyl fumarate attenuates liver injury in a mouse model of cecal ligation and puncture by modulating inflammatory, angiogenic and pyroptotic pathways
Sepsis is a prevalent ailment that significantly affects hospitalized individuals around the globe. It is characterized by uncontrolled inflammatory responses resulting in organ injury and leading to high morbidity and mortality. The liver, a vital organ, is affected by sepsis, resulting in liver dysfunction. Dimethyl fumarate (DMF), which is approved for the treatment of multiple sclerosis, has anti-inflammatory and neuroprotective properties through the inhibition of multiple inflammatory mediators. Hence, the present study aimed to assess the hepatoprotective potential of DMF against sepsis. Four groups of mice (6 animals per group) were divided into a sham group, which was subjected to only anaesthesia and a midline abdominal incision; the cecal ligation and puncture (CLP) group was anaesthetized and underwent an abdominal incision followed by the ligation of the cecum under the ileocecal valve and perforation twice with a needle; the vehicle group was given a solvent of DMF 1 h before the CLP, and the CLP group received 50 mg/kg of DMF via intraperitoneal (ip) injection 1 h before CLP. Following the procedure (24 h post-CLP), the mice were given unrestricted access to food and drink throughout the day. Serum was used to measure the levels of angiopoietin 2, AST and ALT. Enzyme-linked immunosorbent assay (ELISA) was used to investigate the levels of TNF-α, IL-6, MIF, ICAM-1, F2-isoprostanes, VEGF, and caspase 11 in liver tissues. To evaluate the degree of liver damage, a biopsy of the liver was performed. The results revealed that mice exposed to CLP had high levels of AST and ALT in comparison with sham mice. Furthermore, levels of TNF-α, IL-6, MIF, ICAM-1, F2-isoprostanes, VEGF, and caspase 11 in liver tissues were also notably elevated as compared with sham mice. The levels of these parameters were significantly decreased in septic mice pre-treated with DMF. Mice with CLP showed a severe degree of liver damage as compared with sham mice. DMF pre-treatment mitigated liver injury. This study suggests that DMF has hepatoprotective effects on septic mice via the modulation of inflammation, adhesion molecules, angiopoietin 2 and pyroptosis.